Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens

Table 2 Comparison of the changes in serum lipids following initiation of either Efavirenz or Atazanavir based regimens.

		Mean
Continuous Lipid Outcome	ARV Group	Pre	Post	Unadjusted Post Difference	Model 1* Adjusted Difference	p-value	Model 2** Adjusted Difference	p-value
HDL-c (mg/dL)	EFV	39	46	Ref	Ref		Ref
	Unboosted TAZ	39	42	-4	-3.92	0.003	-3.43	0.008
	Boosted TAZ	38	41	-5	-4.12	<0.001	-4.00	<0.001
Non- HDL-c (mg/dL)	EFV	131	136	Ref	Ref		Ref
	Unboosted TAZ	117	131	-5	-1.92	0.55	-1.08	0.73
	Boosted TAZ	126	125	-11	-5.75	0.01	-4.57	0.04
TC/HDL	EFV	4.45	4.02	Ref	Ref		Ref
	Unboosted TAZ	4.45	4.10	1.99	4.41	0.14	3.94	0.19
	Boosted TAZ	4.10	3.97	-1.24	2.62	0.21	3.40	0.11
		Prevalence
Binary Lipid Outcome	ARV Group	Pre	Post	Unadjusted Post Prevalence Ratio	Model 1* Adjusted Prevalence Ratio	p-value	Model 2** Adjusted Difference	p-value
HDL<40 (mg/dL)	EFV	52%	33%	Ref	Ref		Ref
	Unboosted TAZ	55%	39%	1.18	1.05	0.79	1.01	0.95
	Boosted TAZ	53%	42%	1.27	1.18	0.18	1.19	0.17
TC<200 (mg/dL)	EFV	74%	62%	Ref	Ref
	Unboosted TAZ	85%	73%	1.18	1.07	0.59	1.05	0.71
	Boosted TAZ	81%	78%	1.26	1.16	0.09	1.13	0.16

* Adjusted for sex, race, age, history of chronic diseases, pre-initiation HDL and non-HDL cholesterol, CD4, HIV RNA, therapy, and follow-up time
** In addition to variables above, also adjusted for post-initiation CD4, HIV RNA, and type of NRTI backbone

ISSN: 1742-6405